GYRE Analyst Ratings
Gyre Therapeutics, Inc. (GYRE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $706.1M, listed on NASDAQ, employing roughly 579 people, carrying a beta of 5.28 to the broader market. Gyre Therapeutics, Inc. Led by Ping Zhang, public since 2006-04-12.
Consensus: Mixed from 0 analysts.
Price Targets
- Average Target
- $17.00
- High
- $18.00
- Low
- $16.00
How to Read GYRE Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked GYRE analyst ratings questions
- What is the GYRE consensus price target?
- As of the latest aggregator update, Gyre Therapeutics, Inc. (GYRE) carries a consensus 12-month price target of $17.00. Target ranges run from a low of $16.00 to a high of $18.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on GYRE?
- Analyst rating consensus is not currently available for GYRE.
- What recent ratings actions has GYRE seen?
- Recent ratings actions for GYRE are not currently in the snapshot.
- How do analyst targets affect GYRE options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.